MIF and ovarian carcinoma: In particular, the anti-MIF mAb Bax69 was studied in malignant solid tumors (NCT01765790), ovarian cancer (NCT02540356), and metastatic colorectal cancer (NCT02448810) and the anti-CD74 and hence dual inhibitor of MIF and DDT milatuzumab in hematologic malignancies (NCT01101594, NCT00421525, NCT00603668, NCT00868478, NCT00504972, and NCT00989586).